Mark Lee
SVP, Corporate Finance and Development
Replay available
HUTCHMED (China) (HKEX:13) Q4 2022 earnings call, held 2023-02-28. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/hutchmed-china-limited-hcm-q4-2022-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Good day and thank you for standing by. Welcome to HutchMED 2022 Full Year Results Conference Call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, Please press dial 11 again. Please be advised that today's conference is being recorded. I'd now like to hand the conference over to Mr. Mark Lee, SVP, Corporate Finance and Development of HodgeMac. Please go ahead, sir.
0:45 Thank you, Amber. Welcome, everyone. Good morning, good afternoon, good evening. Welcome to the HodgeMed 2022 full-year results and business update presentation. Just at this time I'll mention that the performance and the results of our operations that we'll be talking about today are historic in nature and past performance is not guaranteed. The usage presentation does contain forward-looking statements in relation to the safe harbor provisions and anything that is said and discussed should be heard and read in conjunction with Hachmet's results that we have published on R&S, on NRSEC filings, and in our notes in Hong Kong on Stock Exchange.
1:30 Today we have a broad management team for you to present and answer questions, including Weiguo Su, our Chief Executive Officer and Chief Scientific Officer, Johnny Cheng, our Chief Financial Officer, Karen Atkin, our Chief Operating Officer, Peng Chen, our Chief Commercial Officer, Mike Shi, our Chief Medical Officer and Head of R&D, Jumping Wu, our Executive Vice President of Pharmaceutical Sciences and Manufacturing, and Charles Nixon, our General Counsel. So with that, I'll hand over to Weiguo.
2:07 Okay, thank you very much, Mark. Good morning, good afternoon, good evening, everyone. Welcome again to HutchMed 2022 Four-Year Results Conference Call. A few hours ago, we announced our 2022 Four-Year Results. Mark, can you show the next slide, please? Thank you. And during 2022, HutchMed made significant strategic changes to allow us to better deal with adverse external conditions and to focus on getting to profitability sooner. On the pipeline, We made significant progress, including the positive phase three global registration study for ASCO-2 for frequentinib. And based on the strong data, NDA submissions are planned for 2023, starting from the US, followed by EU and Japan.
3:09 In parallel, our second wave of products, including SolvlaPlanet, mDesilisib, and TES-Metastat, In registration trials in China also made a significant progress. China NDA submissions are planned for 2023 and 2024. Finally, on the China commercial, despite all the challenges associated with COVID and unfavorable exchange rate, our China commercial team delivered strong numbers for our three approved products. Now I'll pass it to Mr. Chen Hong, Chief Commercial Officer of China Commercial to lead it off to give you an update on the China commercial operation. Next slide, Mark, and for Chen Hong.
4:08 Thank you, Weiguo. Hello, everyone. I'm glad to present The 2022 China Commercial Achievement of our three global products. Just as Weiguo said, 2022 was the most difficult year during the last three years due to the COVID-19 infection. Furthermore, the foreign exchange rate is unbearable. Even though our three market products, Quentinib, Zofatinib, and Savotinib still achieved significant sales growth, So firstly, I would like to update you with the HatchMed commercial infrastructure and the capabilities.
4:54 From this slide, we can see more than 900 dedicated and experienced commercial staff covering more than 33,000 oncology specialists and 3,000 key hospitals. The list of hospital pharmacies increased 100% to more than 800 in 2022. In order to mitigate the COVID challenges, many more highly effective academic events were held online for covering more HCT. Next slide, please. For Annulate, it continued to keep strong growth. The sales value was up to 93.5 million US dollars in terms of in-market sales with 32% growth.
5:53 Around 32,000 new patients were treated with Anionate. And we can see Anionate continue to keep leading position in third-line CRC market with 44% patient share according to the latest equivalent checking study. Next slide, please. 2022 was the first year for Celenda listed into NRDL in spite of the 52% price reduction. Celenda still achieved 178% value growth. Around 17,000 new patients were treated and it was recommended by important guidelines such as Cisco and Kaka, et cetera.
6:44 The patient share ranked to be The second in MED market since Q3 last year, which surpassed Zooten and Affinita despite the later launch. Next slide, please. Opposites, as the first in class MED inhibitor in China achieved around 160% growth for its first full commercial year. Inmark's sales value was up to US$41 million. It's recommended by five important guidelines such as NHC, Cisco, Kaka, etc. And more important, it's listed in NIDL this year and will be officially reversed since March 1st, actually tomorrow, with modest price reductions.
7:43 This can be expected that many more patients will be benefited from offset treatment. So overall, in spite of the COVID challenges, we continue to make good progress for all three market products. Along with everything getting back to normal, we are confident the stronger momentum in 2023. So that's all for the China commercial part. Thank you.
8:11 Thank you, Chen Long. Yes, so on this slide number nine, on the right-hand bottom corner, as you all can see, overall with our oncology business, we have recognized 164 million of revenue, up 37% from prior year, in line with our guidance for 2022. As for 2023, our revenue guidance for the oncology business, subject to the closing of the Takeda deal, is $450 million to $550 million. This includes partial recognition of the $400 million upfront income from Takeda, and we continue to target a high double-digit growth from our product sales.
8:56 Moving on to the next page. Page 10, as you all can see, we have over $630 million cash and short-term investment. and 140 million of unutilized banking facilities. In addition, as mentioned, we expect to receive 400 million of upfront income from Takeda at closing. So overall, we have very strong cash resources. Moving on to the next page, page 11, a quick summary of our operating performance. Consolidated revenue up 20% to $400,000. 426 million, of which, as I mentioned earlier, our oncology revenue up 37% to 164 million. Our investment in R&D increased by 29% to 387 million, mainly focused on over 15 registration enabling trials.
9:59 Also, our joint venture increased their net income contribution by 11% to 50 million. So overall, the net loss to the company increased to 361 million, A point to note is that we had a one-time gain from the pilot year on divestment of one of our equity investors. I will now pass on to Karen.
10:21 Thank you, Johnny. Let's go to slide 12, please. Our partnership strategy is focused on three main activities. On the one hand, we have a very successful, long-standing partnership with South Africa, which is in all territories worldwide. For Frequentinib, we've already launched in China in partnership with Eli Lilly and we recently decided to revise our commercial partnership strategy to plan to launch with a single global commercial partner outside of China. We've moved quickly on that strategy to announce a licensing agreement in January with Takeda for the global development, manufacturing and commercialization of Frequentinib in all territories apart from China, Hong Kong and Macau where we will lead the commercialization.
11:06 The decision to include the U.S. alongside other territories in scope for partnerships has meant we attracted a great deal of interest, and we were delighted to have selected such a strong partner as Takeda. Going forward, we will also seek partners for some of our earlier stage assets, as you can see here, for all territories outside of China. For the China partnerships, we're also actively seeking additional late-stage products to inline 100-plus Oncology Commercial Team. Can we go to slide 13, please? The partnership we have with AstraZeneca for savalitinib was announced back in 2011 at a very early stage of development, but has grown from strength to strength with seven registration studies ongoing. AstraZeneca is leading the clinical development outside of China. The nearest term NDA submission opportunity is in late 2024 in the US, Subject to a positive readout for the SAVANA study in non-small cell lung cancer and alignment with the FDA on the potential for accelerated approval.
12:17 Our newest global partnership, you can see on the top line in yellow, was announced on the 23rd of January for frequentinib with Takeda and is progressing very well. We chose Takeda for their strong oncology commercial capabilities in the US in particular, but also in Japan and Europe. They showed us how they would leverage their recent U.S. product launch experiences together with the knowledge of the CRC space they have in Japan to maximize the potential of frequentinib for patients with refractory colorectal cancer but also develop beyond CRC. Takeda are hungry for a major oncology product such as frequentinib and they impressed us with their launch plans. This is a really high-profile, landmark deal for us and subject to regulatory clearances, we will receive an upfront payment of 400 million U.S.
13:10 dollars together with the potential to receive up to an additional $730 million in development and sales-related milestones. We've already started the rolling U.S. FDA submission and we expect to complete it in a few months' time. The FDA typically provides target review completion dates on acceptance of an NDA filing. Subject to U.S. approval, we therefore have the potential to start to book royalties from this partnership from 2024 onwards. I now pass on to Mike for the R&D update.
13:49 Thank you, Karen. Slide 14, please. Yeah, this slide shows the Hushmed Deep and Broad Pipeline advancing the clinic, and these compounds cover broad spectrum of hematology and oncology indications. The first three products Karen mentioned, right, we are already in the market and two are within global partnership. And our next wave of compound has really entered a clinic for the registration trial. And two compounds, our N-Dizelazep and Solvoplanet, both have a CBE, breakthrough destination stage, and we are entering the, finishing the clinical enrollment. EZH2 inhibitors with that is our personalizing product, and we're working with a partner at Epson.
14:40 We have the global China right, and it's currently in the breaking study. We're also running the global China part of the study in the second line in FOMA. The third wave compound is also expanding very rapidly. The FGFR inhibitor, 306-IDH12 inhibitor, are third generation EDK inhibitor 760 and CSF1R inhibitor 653 are all potentially entering pivotal trial stage this year. Next slide. And colorectal cancer is the third most common cancer worldwide with over 900,000 deaths. And the third five year survival rate is very poor.
15:26 and most of the recent advances in CRC are focused on the small patient population with actionable mutations such as BRAF, MSI for HER2. But the majority of the metastatic colorectal cancer patients, the treatment options are very limited. Essentially, they actually remain the same, almost the same, about a decade ago with rovorapidinib and long-serve as the proof for third-line therapy. So there's still very high unmet need in the late-stage metastatic cancer patients. Next slide. So our first global MRCT FRESCO II trials was presented at ASMO last year and demonstrates the frequency that has the statistically significant and clinical and meaningful increase of the primary endpoint over survival and key secondary endpoint PFS compared with the placebo in late-line CRC patients.
16:20 So the magnitude improvement of all clinical endpoints OS, PFS, and DCR are clearly standing out for fluquitinib in comparison with existing therapy. And also because the fluquitinib is a very specific VEGF inhibitor of 1, 2, 3, it has less off-target toxicity and is well-tolerated with a safety profile consistent with previous therapy. Slide 17. The first cold trial was started after the consultation with the U.S., EU, and Japan health authorities and confounded across the globe. And the results are highly consistent with the China pivotal trial fresco and also the U.S. bridging study. And we also believe this is a truly proudest changing.
17:06 FDA previously granted a fast track designation for third line plot CRC. TouchMED has already started rolling submission and we are planning to complete this submission. U.S. NDA first half of the year and also followed with the EU and Japan completion this year. Next slide. In November 2022, we announced the top-line results of another Coquitamin phase 3 trial in the second-line gastric cancer in China. The gastric cancer is the fifth most common diagnosis cancer worldwide with over a million new cases globally. And China alone accounts for 44% global cases also very high prevalent in the Asian countries.
17:52 Futiga is the double-blind, second-line trial, placebo-controlled trial in combination with Paclitaxel. And the trial met one of the dual primary endpoints with a significant improvement and clinical meaningful PFS improvement. And also have other secondary endpoints with OR, DCR, have a statistically improvement and also will include the durable response. And the safety profile of the creatinine in the FUTIKA trial is also very consistent with the previous reported study. So based on that, HACHMED is preparing to file the supplementary MDA with NMPA the first half of this year. Next slide. And this slide shows the semi-registration trial of our MED inhibitor savalitinib in all currently enrolling. And three led by AstraZeneca globally and four led by HACHMED.
18:48 and with the robust SIRVANA trial reported at WCLC last year, the AstraZeneca needed a new cohort of the SIRVANA to really aim for evaluate the potential accelerated approval. And solid and also be granted a fast track destination by FDA for the combination treatment of Tuglesol in Tuglesol refractory non-small cell lung cancer patients. And also reinforce the first one, The second trial is the second and third line Tigrisyl plus salvalidinib in the refractory, Tigrisyl refractory non-force ultrasound with med aberration. And also we reached the milestone payment for AstraZeneca last year.
19:36 And the other registration trial, SAMITA, in the patellar renal cell carcinoma led by Izzi, and also the other trial, the SACHI, Sarnovo in lung cancer, are all continually enrolling, led by Hachimed. And also, we are entering the registration phase for the gastric cancer with metamplification for salvo inhibitors. Next slide. We are very excited about the second wave of compounds that are advancing the late-stage development. SalvoPlanet is a highly differentiated horror-sick inhibitor with the breakthrough destination for ICP in China. ITP is a required autoimmune disorder characterized by low platelet count resulting from platelet discretion and impaired production.
20:24 There are about an estimate of 2 to 5 per 100,000 persons in the general population. So we are very encouraged by our Phase I-II results demonstrating the robust ORR of 80% and the Bureaucrat response rate 40% in relapsed refractory primary ITP patients. This is really on par with the current existing widely used ITP second-line treatment like T4RA. And also the same response rate that shows in the patients who were refracted or treated as TPO. So it's a very robust product. So we are very excited. We completed enrollment for the phase three registration trial EZLIM-01.
21:10 in December last year, and we prepared for the potential readout and NDA filing in China data this year. PSY21. The other compound is endosilicid. It's a differentiated PR3K delta inhibitor. It's currently ongoing in two single-arm phase two registration study in China, third-plastline follicular lymphoma and second-line marginal zone lymphoma. The data we published before showed the compound is not only promising with efficacy, but also has a favorable safety profile when compared with the same class of a compound, as highlighted in the low incidence of AE of interest, such as diarrhea and liver enzyme increase, as well as low discontinuation rate.
21:57 So of course, this needs to be further characterized in the larger patient population, and we are excited to report that we have completed enrollment for this pivotal trial in third-line follicular lymphoma yesterday, we reported yesterday, and the clinical readout and potential NDA filing will be later this year. Next slide. And Pasmetastat is our in-line EZH2 inhibitor from Epizyne. And currently it's in the bridging study we're anticipating to file next year. And also, Epizyne is Ipsen reported as ASH. It's very robust. We are also exploring Tasmetastat in combination with R-squared in the second-line follicular lymphoma. And we are part of the global Symphonate 1 trial to really testing in the second-line setting.
22:50 And so we are also exploring Tasmetastat in combination with our PSUK Delta inhibitor and Dizelaza in the relaxed refractory lymphoma patient. Next slide. Our clinical development continued to grow. And in addition to the positive readout for recruitment trial in the CRC and gastric cancer, this slide showed the 15 ongoing plus, ongoing registration trial in the six leading compounds, including the lifecycle indication of market products and of the late stage assets. And with the anticipated NDF following timeline in the next few years. Slide 24.
23:38 So I'm highlighting the deliverables for 2023 for R&D. On the regulatory activity, we'll complete the registration filing for frequentinates in all major global markets, U.S., EU, and Japan for third-line CRC. We'll initiate the supplementary NDF filing in the first half for the frequentinates in the second-line gas retention in China. We'll also initiate The PMDA consultation for psorafatinib in the May year based on the Japan Breeding Study and the SANAI Trial Registration Guide in China. And also, importantly, we anticipated data readout and potential MDF filing in China for sorboplantase in second-line ITP and MDXelicin in third-line folliculite in FOMO-tibetal troposylate for later part of this year.
24:33 And also on the development side, Hodgman and our partner continue to complete enrollment for multiple registration trial for cell validity in non-smart cell lung cancer. And also we'll complete multiple trials like the buquitinib plus scintillamab in individual cancer and RCC. So on the team side, we also advance our pipeline with endozilazep, imenzil, and tasmetazep-reaching study. And we also have a herd need-out for our Savalingen and Mono therapy in meta-embolicized patients and also Saval Planet in the AIHA Advancing to Phase III class. So recap the R&D progress. HatchMED has a deep on board portfolio and multiple near-term catalysts for this year.
25:21 And our R&D team will remain a laser focus on the execution of our laser development product. So with that, I'll turn to Dr. Weiguo Su, our CEO and the CFO.
25:34 Okay, thanks, Mike. Just to sum it up, HutchMed took necessary steps in 2022 focused on getting to profitability and becoming self-sustaining. Now, we have a lot to execute and deliver on our pipeline. We believe these launches of new products, next slide, Mark, you know, As Mike just showed you, we have many registration trials ongoing leading to NDA submissions both in China and globally in the next few years. And clearly we have a lot to execute and deliver on our pipeline.
26:22 We believe these launches of new products and new indications will position us to continue to grow our China commercial. And we also expect to start receiving royalties from our XChina sales of our partner products, Savalitinib and Fluquentinib. And we believe these changes will not only help us get through tough market conditions, but also ensure that we emerge a stronger company. And with that, I would like to thank you all for your attention, and the management team is available to take questions. Thank you. We will now begin the question and answer session.
27:09 To ask a question, please press star 11 on your telephone and write for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. Once again, the star 11 for question. Our first question comes from the line of Kelly Xu from Jefferies. Please ask your question, Kelly.
27:38 Thank you for taking my questions and congrats on a great year. Regarding HatchMED's commercial infrastructure for oncology franchise, have you achieved the optimal targets in terms of the number of covered hospitals and healthcare providers? And where would be your other focused area in 2023 to grow those further? And also, could you talk about when do you expect a company to become profitable? Thank you.
28:09 Okay. Thanks, Kelly, for the questions. Just very quickly on commercial structure, I'll probably give a quick answer and see if Changhong has anything else to add. So basically, we are around 900 FTEs supporting Furu Quintinib and Surufatinib. And we should be able to support even more indications for these two products. With regard to further build out, I think, you know, given that our next wave of products, Solvliplanib, Emdesilisib, and Tasmetastat, all in hematologic indications. So we actually plan to build up a specialty team to support our next wave of compounds in heme indications.
29:04 With regard to specific timeline for profitability, we are targeting 2025. Obviously, we need to continue to grow our China commercial to increase revenues, but also I think the timing of our ex-China products to start to contribute The income, I think that matters as well, including savalitinib and fluquantinib, but we believe both will start to contribute royalties to us late 24 and certainly 25. So again, our target is 2025.
29:51 Maybe Changhong or Johnny, if you have any Anything else to add with regard to commercial infrastructure in China? Are we covering all the hospitals now and anything else where we need to beef up?
30:13 Thank you, Weiguo. I think for now, our commercial infrastructure is optimal for current products, launched products. as well as indications and we continue to improve our efficacy for this team and to catch up the market opportunities and definitely we will increase with more opportunity coming or more products coming so it's on the way to Thank you.
31:06 Our next question comes from the line of Louis Chen from Canto. Please ask your question, Louis.
31:19 Okay, thank you and congratulations on all the progress this quarter. So I wanted to ask you a few questions. First one, just to follow up on the first question that Kelly had asked you, are you expecting profitability for the full year 2025? And then I also wanted to ask you, you have a lot going on this year, very busy. I wanted to ask you, you know, what are your key, you know, most important readouts or approvals that you're looking forward to this year? And then last question is, how are you thinking about operating expenses year over year? Thank you.
31:51 Okay, thank you for these questions, Louis. I'll ask Johnny to provide some more details on these questions.
32:02 Okay, so first, regarding profitability, 2025 is consistent with what we have communicated to the market for the last couple of years. That remains our target. to be able to break even and turn around to become profitable in 2025. And as I said, this is our target. And we haven't changed our target for the last couple of years. And in terms of the OPEX year on year, I think for 2023, you can expect the level for OPEX operating expenses will be similar. By and large, overall will be similar Thank you, Johnny.
33:20 Our next question comes from the line of Alec Stranahan from Bank of America. Please ask your question, Alec.
33:29 Hey, guys. Thanks for taking our questions. Just a few from us. First, what's left for the rolling submission for frequent nibs? And just remind us whether you guys are handling the submission yourself or if Takeda or a combination of both are doing the submission. Second, on AmDigitalDigital, The follicular lymphoma readout, I think, is second half of this year. Is this just due from the pace of the enrollment or when the study started, or is it a prioritized indication for you guys at this point? And would you file in follicular lymphoma next year if the data looks good, or would you wait for, say, MZL to read out as well? And then just lastly, on the business update, obviously some tradeoffs with giving up economics to partners.
34:18 Thanks Alex for the questions. Let me ask Mike to take your questions first.
34:40 Yeah, so just to answer your question for frequent event submission, we already started rolling submissions because we have the fast track designation. So, you know, as you know, the Takeda deal has not yet been finalized. So we already hit on four cylinders, right, to do the submission. The NDA submission, the EU submission, and Japan submission, we already get started. We also plan a lot of things. For example, the EU market assesses all these programs has been ongoing. And of course, you know, when the final transaction happens, we'll certainly discuss with our partner about how we can really accelerate the registration process. For example, you know, Takeda has a very strong presence in Japan. We do think, right, with their expertise in all the markets, we're going to accelerate the registration process without slowing it down.
35:42 And, you know, to answer the question for Ken DeZillis, we just finished phase two follicular lymphoma enrollment. We're anticipating a readout. You know, again, I remind you, this is the third line follicular lymphoma We previously have agreement with the CDE about the trial design. If the trial is, you know, have a, you know, positive readout, we're going to submit later this year for the CDE for the approval. And, you know, I also mentioned, right, for endosylicis, we are still, we also have other combination trial going on. But for the base of the submission, it will be all the data will be have, right, for the particular folliculitis lymphoma, and also all the patient data what we have to support the NDA package.
36:38 And the, you know, for the development prioritization, what we really focus on the late stage product, where we can, how we can really, you know, in the near term drive the value for all these late stage product and, you know, towards what Dr. Su mentioned, towards the break-even point by 2025. So, we have multiple products in the development. We hope our registration and salary the developer will support our path to further sustain the profitability.
37:14 Okay. Thanks, Mike. Maybe just add a couple of points, Alex, regarding MDIS ELISIB filing strategy. Certainly, FL will be first. Marginal Zone will be actually a second NDA will be sometime likely next year or late next year. So these will be filed separately instead of together. Regarding prioritization, portfolio prioritization, we will plan an R&D day sometime this year to Thank you. Next question comes from the line of Yang Huang from Credit Suisse.
38:00 Please ask your question, Yang.
38:27 Thanks. I have two questions. First one, management just guided for this year on college revenue will be 450 to 550, but with some partial recognition of Takeda upfront payment. Can you give us some more color on how you're going to kind of recognize partially and what's going to be More color can we have in terms of product sales for this year's guidance? That's my first question. Thanks.
39:09 Okay. Maybe Johnny can provide some details on the 450 to 550 million guidance as well as our expectation for 2023 product sales.
39:26 Okay, thank you, Dr. Xu. So for 400 million upfront income, the accounting recognitions would have to take into consideration of the performance obligation under the terms of the licensing agreement. So that as the closing has yet to happen, so our auditor have to determine when it actually happens and the Thank you. Thank you very much. So in terms of the product sales, as you have looked at our recognitions of the product sales, Hachimed level is about 63% growth versus last year. We continue to project a high double-digit growth in 2023. So basically in the range of You know high double-digit
40:57 estimation as we are not giving specific guidance to this so you can estimate that the level of projection growth you have to take into account basically you have to take into account LNA surrender already entered it into the NLDL and our partners would be in the first year starting from March that they would be They would be able to, the patients will be able to gain access from benefits from the NRDL.
41:31 Thanks, Johnny. I think, you know, given the opening of China, COVID's impact is going to diminish this year and, you know, In January, we had COVID outbreak and also Chinese New Year as well. But we expect conditions to become far better this year compared to last year. So we expect similar levels of growth this year, if not better.
42:10 Okay, got it. Yeah, that's helpful. My second question is, The company is going to file S&DA for Quintinib in gastric cancer. It looks like a larger indication. Can the company comment on how should we compare the commercial kind of prospect for Quintinib in terms of gastric cancer compared with its current indication in CRC?
42:41 Sure. Maybe, Mike, you can take this question.
42:48 Yeah, so for the gastric cancer, right, and in the second line, you know, current approved, you know, product is really paclitaxel and also rempaclitaxel, right? So, you know, it was approved last year, the rempaclitaxel, and, you know, we look at, I think that for Quintinet, but it's really, you know, started the trial when the paclitaxel was the, You know, stand-up care. So the trial was a positive and needed one of the bureau primary endpoint. It is a large indication for second-line gastric cancer. So, as I mentioned, you know, 44% of patients globally in China and also is representing is a huge opportunity in terms of patient volume and, you know, for For the commercial side, I think the company will plan accordingly for the NDA submission and the follow-on commercial part.
44:04 Briefly, second-line GC patient population size should almost double that of third-line CRC or later-line CRC. You know, less competitive treatments available also, other than Paclitaxel is still standard of care. And as Mike mentioned, Paclitaxel plus ramsurumab was approved last year, but it is highly priced and it is far from standard of care in China. So we view it as a great opportunity here.
44:49 Okay, I see. Just a quick follow-up. Have we got any feedback or had any meeting with the CDE in terms of gastric cancer finding?
45:01 No, the answer is no. We are actually focusing on preparation of CSR and just to get ready for some mission.
45:10 Okay, got it. Thanks. All right, thank you. Our next question comes from the line of Mike Mitchell from Premier Gordon. Please ask your question, Mike.
45:24 Thanks. Thanks, everyone, and thanks for taking my questions. I just wanted to know, from your perspective, what the likely steps are regarding the SEC and the U.S. accounting oversight issue. I know you've put a comment in today's statement, but if you have any more on that, that would be great. And just a second question, actually, just to follow up to the previous question. Q&A. I just wanted to return to the tequila deal. Just on the point of partial recognition of the upfront, would there be material obligations still to be completed in 2024 relating to the upfront payment? I'm just trying to understand exactly what those would be. So any more color on that would be helpful. Thanks.
46:04 Okay. Thanks, Mike. Maybe Johnny? Yes. Okay. Thank you, Dr. Xu.
46:09 So FCAA From the PCAOB, we heard it from December last year that they have come to this side of the world and basically they have revealed and they were able to gain access. This is what we have known and we do not foresee issues in terms of the US authorities gaining access to the audit working paper of the auditors of the company that they have selected. This is as far as we have known. Our resources and our auditors have not able to give us more color on this, but we believe that this issue, based on the announcement by the PCOP last year, actually we have no further negative news regarding this issue.
47:07 So in terms of the... Revenue Recognitions in terms of this performance obligation. Basically, by and large, I think 2023-2024 is all related to the regulatory submission as well as some of the approval step that requires us to follow up. So some of which I think may lead to 2023 and also, of course, some Items related to technical transfer, for example. They are all the considerations that the auditor would assess. As I said, the closing timing hasn't occurred yet, so we are not in a position to actually comment in great detail about the recognition method and the extent that we can recognize for this year.
48:06 I hope that answers your question. Thank you. Thanks, Charlie. Thank you. Our next question comes from the line of Roderick Marr from Goldman Sachs. Please ask a question, Roderick.
48:27 Hi. This is Roderick for Powell. And just two questions from us. So since you already started the rolling summation for fruit continent in the US, Have you heard any FDA feedback on the submission? And the second question is for the NRDL inclusion of sevalatinib. Just, are there any, like, details on the price maybe will be provided at some point? Thanks.
48:56 Okay, thanks for the question. For the US NDA for fluquantinib, I'll ask Mike to provide some feedback.
49:06 Yeah, so we are, you know, it's going smoothly. And we already have the, you know, first module submitted. And as what I said, right, this is all went through, you know, we'll continue to targeting to, you know, finish those, the other modules, you know, the first half of this year. So, so far, it's been going on smoothly.
49:35 Okay. Yeah, typically you don't hear anything until you finish or complete filing. With regard to SAVA NRDL, we agreed with AstraZeneca not to disclose the price after negotiation. However, it will become available tomorrow, I assume March 1st, so you probably will be able to find out
50:10 Thank you. Our next question comes from the line of Matthew Yen from CLFA. Please ask your question, Matthew.
50:25 Hi, thanks for taking my questions and congratulate on the results. I got two questions. First is regarding the supplementary filing for secondary gastric cancer for Fucundinib. I wonder what's your view regarding particular results that met the primary endpoint of PFS but not overall survival. So do you think that CDE is very likely to agree that PFS will be enough to support this filing this year? And my second question is regarding the PICUK and this Elizabeth. I wonder can you elaborate more on How will it differentiate itself in the China, PIC, Ukraine market, especially because there are more leading peers approved and about to be approved from FPG, Hung Lee, or Hineman?
51:15 Yeah, those are my two questions. Thanks.
51:19 Okay. Thanks for the questions. And I'll ask Mike again to provide his view on PIC. Second line GC for frequentinib and also emdesalicib differentiation.
51:36 Yeah, so for the second line gastric cancer, so, you know, for the lot of, you know, trials, if you can see, particularly done in Asia, right, because the subsequent treatment is very high compared with the global, So, so far, if you look at all the Asian trials, including the subset of patients in the RIMBO trial, right, the global trial, is all, you know, you know, even for Rancilera plus Paclitaxel and the RIMBO Asia trial, as you can see, is the PFS significant and the OS is not significant.
52:26 This is particularly related to the treatment paradigm in Asia. So we think this is, you know, as what we have, this design, right? We have a lot of the factors looking to it. I think this is really reflecting the practice in Asia and in China. So from what we have, we do think this is the, you know, The GFS as a primary endpoint is one of the Dior endpoints. We have built-in statistical analysis to really adjust the, you know, the offers for this critical design. And it was a trial design with a readable bit CDE. So we do, you know, intend to using these trial data to submit for the second line GC and pretty much benchmarking for the Rainbow Asia, if you look at that data, right?
53:23 And it's approved in China, like what I mentioned last year. And go back to end of Zillow, right? So the data will be reported is really, if you look at the comparison with the competitor, the safety profile is really quite, you know, not only the efficacy is quite robust, but also the safety profile. Some of the, you know, areas of interest like diarrhea, liver enzyme increase, we do see on the Zolizib, it looks very favorable. And, you know, in the treatment landscape, again, right, the single arm, you know, registration for phase two trial was discussed and agreed upon with the CDE design and the You know, at the moment, right, we also received the breakthrough therapy in China, right? So we do, based on the safety profile and the robust clinical advocacy, we are intending, you know, of course, if you look at the CDE discussion recently, we are also, you know, preparing for conditional approval and the potentially confirmatory trial.
54:44 So at this stage, right, you know, based on the timeframe what we have, we do think this is a, you know, it's a good opportunity to file based on the single arm followed with the confirmatory trial and to confirm this study, yeah.
55:02 Thanks, Mike. Thank you. I'm showing no further questions. I'll now turn the conference back to Mark for closing remarks.
55:21 Okay. Thanks, Amber. Weiguo, any comments or you can close, I think.
55:28 Well, you know, again, thank everyone for attending the call. 2022, we made really significant strategic changes and now we believe we are well positioned to execute on our plan towards profitability. We have a lot to deliver in our pipeline including our three approved products with additional lifecycle management indications as well as our second wave of products now reaching NDA stage all in parallel with our third wave of compounds entering So we're really positioned to grow, actually to accelerate our growth in China and outside China.
56:21 And this will actually see us all the way through 25, even beyond 26, 27 with all these third wave of compounds lined up for registration studies and potential NDA. Submissions in China. So we're really confident that we will be able to deliver on our pipeline and also our China commercial team led by Chen Hong is really high performing, worked through 2022 with all the difficulties and they are Again, also positioned to grow very quickly, very rapidly with new launches of new indications and also new products in the next few years.
57:11 So, all in all, we got through 2022, very difficult year, but now we believe we are on our way to profitability and we are a much stronger company today. Thank you all for your attention. And if you have any further questions, reach out to us, to Mark's team or to myself. Thank you. All right. Thank you. So this concludes today's conference call. Thank you for participating. You may now disconnect.
Follow HUTCHMED (China) Limited into a list and get an email when it puts out news.
SVP, Corporate Finance and Development
Chief Executive Officer & Chief Scientific Officer
Chief Commercial Officer, China
Chief Financial Officer
Chief Operating Officer
Chief Medical Officer & Head of R&D
Analyst, Jefferies
Analyst, Canto
Analyst, Bank of America
Analyst, Credit Suisse
Analyst, Premier Gordon
Analyst, Goldman Sachs
Analyst, CLFA